T cells responding to antigen in vivo down-regulate L-selectin, the lymph n
ode homing receptor, as they develop into activated effector cells. The con
comitant up-regulation of the proinflammatory adhesion molecules LFA-I, CD4
4, and VLA-4 suggests that, after their release into the circulation, they
traffic to sites of antigen deposition and inflammation. Previous evidence,
however, has suggested a role for L-selectin in the recruitment of both ne
utrophils and lymphocytes into sites of inflammation, which would indicate
that these L-selectin(-) effector cells could not be the precursors of infl
ammatory cells. We therefore directly tested whether L-selectin(-) T cells
activated in vivo are capable of homing to model inflammatory sites. L-sele
ctin(-) cells isolated from mice primed with alloantigen or with a contact
sensitizer migrated to inflammation markedly better than L-selectin(+) cell
s from the same animals. Furthermore, the analogous population of CD44(hi)i
ntegrin(hi) cells from intravenously primed L-selectin knockout mice traffi
c efficiently to inflammatory sites and reject allogeneic skin grafts with
normal kinetics. These data demonstrate that the previously described L-sel
ectin(-) population of T cells that differentiate into effecters in spleen
and lymph nodes subsequently traffic to inflammatory sites, due in part to
their increased expression of other proinflammatory adhesion molecules.